Literature DB >> 21061073

Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.

Vaibhav Gaur1, Anil Kumar.   

Abstract

Cerebral ischaemia is a leading cause of death and disability. The objective of the present investigation was to explore the neuroprotective potentials of candesartan and atorvastatin alone and their combination against the cerebral ischaemia induced behavioral, biochemical, and mitochondrial dysfunction. Male Wistar rats (200-220 g) were subjected to bilateral common carotid artery occlusion for 30 min followed by 24 h reperfusion. Candesartan (0.1 and 0.3 mg/kg) and atorvastatin (10 and 20 mg/kg) were pretreated for 7 days before animals were subjected to ischaemia reperfusion injury. Various behavioral tests (locomotor activity and rotarod performance), biochemical parameters (Malondialdehyde levels, nitrite concentration, superoxide dismutase and catalase activity, redox ratio, and GST) and mitochondrial enzyme (Complex I, II, III, and IV) dysfunctions were measured in cerebral cortex, striatum and hippocampus of the ischaemic brain. Seven days candesartan (0.1 and 0.3 mg/kg) or atorvastatin (10 and 20 mg/kg) pretreatment significantly attenuated neurobehavioral alterations, oxidative damage and restored mitochondrial enzyme dysfunction as compared to control (I/R) group. Further, combined treatment of candesartan (0.1 mg/kg) and atorvastatin (10 mg/kg) significantly potentiated their protective effect which was significant as compared to their effect alone. Present study suggests the protective effect of candesartan and atorvastatin and their combination against ischaemia reperfusion induced behavioral and biochemical alterations in rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21061073     DOI: 10.1007/s10787-010-0068-y

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  55 in total

1.  Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.

Authors:  Hua Hong; Jin-Sheng Zeng; David L Kreulen; David I Kaufman; Alex F Chen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-09       Impact factor: 4.733

2.  Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors.

Authors:  Y Nishimura; T Ito; K Hoe; J M Saavedra
Journal:  Brain Res       Date:  2000-07-14       Impact factor: 3.252

3.  Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury.

Authors:  K Baker; C B Marcus; K Huffman; H Kruk; B Malfroy; S R Doctrow
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

4.  Neuroprotective effect of Azadirachta indica on cerebral post-ischemic reperfusion and hypoperfusion in rats.

Authors:  Sudhirkumar Yanpallewar; Sunita Rai; Mohan Kumar; Satish Chauhan; S B Acharya
Journal:  Life Sci       Date:  2005-01-18       Impact factor: 5.037

Review 5.  Neuroprotective properties of statins in cerebral ischemia and stroke.

Authors:  C J Vaughan; N Delanty
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

Review 6.  Free radical pathways in CNS injury.

Authors:  A Lewén; P Matz; P H Chan
Journal:  J Neurotrauma       Date:  2000-10       Impact factor: 5.269

7.  Behavioral, biochemical and cellular correlates in the protective effect of sertraline against transient global ischemia induced behavioral despair: possible involvement of nitric oxide-cyclic guanosine monophosphate study pathway.

Authors:  Vaibhav Gaur; Anil Kumar
Journal:  Brain Res Bull       Date:  2010-02-01       Impact factor: 4.077

8.  Protective effect of naringin against ischemic reperfusion cerebral injury: possible neurobehavioral, biochemical and cellular alterations in rat brain.

Authors:  Vaibhav Gaur; Aditi Aggarwal; Anil Kumar
Journal:  Eur J Pharmacol       Date:  2009-07-03       Impact factor: 4.432

9.  Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.

Authors:  Soon-Tae Lee; Kon Chu; Jung-Eun Park; Nan Hyung Hong; Woo-Seok Im; Lami Kang; Zhe Han; Keun-Hwa Jung; Min-Wook Kim; Manho Kim
Journal:  J Neurochem       Date:  2007-11-01       Impact factor: 5.372

10.  The usefulness of operant conditioning procedures to assess long-lasting deficits following transient focal ischemia in mice.

Authors:  André Ferrara; Sophie El Bejaoui; Sandrine Seyen; Ezio Tirelli; Jean-Christophe Plumier
Journal:  Behav Brain Res       Date:  2009-08-15       Impact factor: 3.332

View more
  9 in total

Review 1.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

2.  Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.

Authors:  Jitendriya Mishra; Tanya Chaudhary; Anil Kumar
Journal:  Neurotox Res       Date:  2014-02-25       Impact factor: 3.911

3.  Coffee component 3-caffeoylquinic acid increases antioxidant capacity but not polyphenol content in experimental cerebral infarction.

Authors:  Silvia Ruiz-Crespo; Jose M Trejo-Gabriel-Galan; Monica Cavia-Saiz; Pilar Muñiz
Journal:  Neurochem Res       Date:  2012-05       Impact factor: 3.996

4.  Angiotensin II-mediated suppression of synaptic proteins in mouse hippocampal neuronal HT22 cell was inhibited by propofol: role of calcium signaling pathway.

Authors:  Xiaowei Ding; Xingzhu Ju; Yan Lu; Wei Chen; Jiaqiang Wang; Changhong Miao; Jiawei Chen
Journal:  J Anesth       Date:  2018-10-06       Impact factor: 2.078

5.  Amelioration of stroke-induced neurological deficiency by lyophilized powder of catapol and puerarin.

Authors:  Yang Liu; Qiang Xue; Xu Li; Jifen Zhang; Zhifeng Fu; Binbin Feng; Yi Chen; Xiaoyu Xu
Journal:  Int J Biol Sci       Date:  2014-04-08       Impact factor: 6.580

6.  Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.

Authors:  H A Murad; Z J Gazzaz; S S Ali; M S Ibraheem
Journal:  Braz J Med Biol Res       Date:  2017-09-21       Impact factor: 2.590

7.  Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity.

Authors:  Tatsuya Fukuta; Tomohiro Asai; Takayuki Ishii; Hiroyuki Koide; Chiaki Kiyokawa; Masahiro Hashimoto; Takashi Kikuchi; Kosuke Shimizu; Norihiro Harada; Hideo Tsukada; Naoto Oku
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

Review 8.  The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies.

Authors:  Stefan Wanderer; Basil E Grüter; Fabio Strange; Sivani Sivanrupan; Stefano Di Santo; Hans Rudolf Widmer; Javier Fandino; Serge Marbacher; Lukas Andereggen
Journal:  Brain Sci       Date:  2020-03-07

9.  Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress.

Authors:  Evelyn Nunes Goulart da Silva Pereira; Beatriz Peres de Araujo; Karine Lino Rodrigues; Raquel Rangel Silvares; Carolina Souza Machado Martins; Edgar Eduardo Ilaquita Flores; Caroline Fernandes-Santos; Anissa Daliry
Journal:  Nutrients       Date:  2022-02-08       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.